*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
We wanted to give you a quick intraday update on our new alert, Dyadic International, Inc. (Nasdaq: DYAI).
DYAI opened today at 1.00 and rallied to a high so far of 1.16, up +16%.
This is exactly the type of opportunity we were looking for!
In addition, this morning, DYAI announced breaking news that could be an added growth catalyst for the company.
Here is the news from this morning:
“Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential”
“JUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today highlighted continued progress across multiple global health collaborations that further validate the capabilities of its proprietary C1 protein production platform while supporting its broader commercialization strategy.”
As the company further explains:
“Dyadic's C1 platform is designed to enable rapid, high-yield, and cost efficient production of recombinant proteins, vaccine antigens, monoclonal antibodies (mAbs), therapeutic proteins, enzymes, and other biologics. By accelerating strain development and efficiently secreting target proteins, C1 has the potential to address one of the industry's most significant challenges: manufacturing biologics faster, at larger scale, and at lower cost.”
“The Company believes its fully funded emerging infectious disease preparedness initiatives, including programs targeting Ebola and hantavirus, are providing real-world demonstrations of C1's potential advantages in rapid response. These collaborations are intended to showcase how C1 may accelerate the development and production of critical biologics when speed, flexibility, scalability and manufacturing efficiency are essential.”
Recent Global Health Collaboration Highlights
Gates Foundation-supported monoclonal antibody programs:
“Dyadic's Gates Foundation-supported research programs are evaluating the use of C1 for global health monoclonal antibody applications, including RSV and malaria. The Company has received the full $3.1 million Gates Foundation grant, including the final payment of $738,743 in June 2026, which is expected to fully fund the ongoing research.
To date, studies have shown that C1-produced monoclonal antibodies demonstrated binding and neutralization characteristics comparable to antibodies produced using traditional CHO cell systems. In addition, the C1 platform has demonstrated higher production yields at lower projected manufacturing costs, with multiple production runs completed during the timeframe typically required for a single CHO manufacturing cycle.”
Coalition for Epidemic Preparedness Innovations (CEPI)/Fondazione Biotecnopolo di Siena (FBS) Program:
“As part of CEPI's 100 Days Mission and the $4.5 million CEPI/FBS/Dyadic collaboration, researchers have demonstrated plasmid-to-purified-protein production in approximately 15 days using the C1 platform. This milestone highlights the potential of C1 to significantly reduce development and manufacturing timelines for vaccine antigens and monoclonal antibodies, while supporting improved productivity and cost efficiency.”
Scripps Research Bundibugyo Ebola Collaboration:
“In Dyadic's recently announced collaboration with Scripps Research focused on Bundibugyo Ebola preparedness, the Company is applying its rapid C1 workflow to produce complex viral antigens for evaluation in non-mRNA vaccine studies. Dyadic currently expects to deliver initial purified antigen samples to Scripps by the end of July 2026, providing an additional opportunity to demonstrate C1's ability to support accelerated outbreak response efforts.”
European Vaccines Hub and FBS Preparedness Initiatives:
“Dyadic's participation in global preparedness initiatives, including initiatives involving the European Vaccines Hub and Fondazione Biotecnopolo di Siena, continues to expand awareness and validation of the C1 platform for high-priority infectious disease applications, including vaccine antigen and monoclonal antibody opportunities targeting Ebola, hantavirus and other emerging threats.”
Addressing a Growing Manufacturing Challenge:
“While advances in artificial intelligence, genomics, and molecular biology continue to accelerate the discovery of innovative vaccine and therapeutic candidates, biologics manufacturing remains a critical industry bottleneck. The ability to rapidly produce sufficient quantities of high-quality biologic therapies often determines how quickly they can reach patients.
Dyadic believes C1 is uniquely positioned to help address this challenge through a microbial, non-mammalian production platform engineered for speed, scalability, productivity, and manufacturing efficiency.”
Expanding Commercial Opportunity:
“The global biologics market exceeds $690 billion and is projected to surpass $1.3 trillion by 2033. Monoclonal antibodies account for more than 65% of biologic sales, while recombinant proteins, vaccines, enzymes, and other biologics continue experience significant growth.
Dyadic believes the C1 platform can support multiple avenues for value creation across biologics manufacturing, recombinant protein, vaccine antigen, monoclonal antibody, therapeutic enzyme, and life sciences protein markets, representing an addressable opportunity of more than $25 billion.
The Company's commercialization strategy is designed to progress from platform validation to revenue generation through partner-funded development programs, product sales, commercial manufacturing collaborations, platform and strain licensing, royalties, and broader adoption across life sciences and biopharmaceutical markets.”
Here are some of the company’s comments from this press release:
"Emerging outbreaks such as Ebola continue to remind us that discovery alone is not enough," said Mark Emalfarb, Founder and Chief Executive Officer of Dyadic. "The real challenge is translating a genetic sequence or plasmid to high-quality product that can be developed and manufactured rapidly, affordably and at scale. Through our collaborations with organizations such as Scripps Research, CEPI, Fondazione Biotecnopolo di Siena, the Gates Foundation, and the European Vaccines Hub, we believe C1 is increasingly demonstrating its value as a faster, more flexible, and potentially lower-cost platform for biologics manufacturing, outbreak preparedness, and commercial applications."
We are continuing to monitor DYAI for a sustainable breakout higher.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 7/1/26 for the distribution of this advertisement about DYAI dated 7/7/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.